KR920019770A - 포스포리파제 a₂억제제로서의 테트론산 및 티오테트론산 유도체 - Google Patents
포스포리파제 a₂억제제로서의 테트론산 및 티오테트론산 유도체 Download PDFInfo
- Publication number
- KR920019770A KR920019770A KR1019920005991A KR920005991A KR920019770A KR 920019770 A KR920019770 A KR 920019770A KR 1019920005991 A KR1019920005991 A KR 1019920005991A KR 920005991 A KR920005991 A KR 920005991A KR 920019770 A KR920019770 A KR 920019770A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- hydroxy
- furanone
- oxo
- thiophenone
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/40—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/60—Two oxygen atoms, e.g. succinic anhydride
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/32—Oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Furan Compounds (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (61)
- 일반식(I)의 화합물.상기식에서, X는 -CH2R이고,R은이며, 추가로 Y가 S인 경우, R은 -(CH2)eCH3일 수 있고, Y는 -O-또는 -S-이며, R1및 R2는 각각 독립적으로 수소 또는 저급 알킬이고, R3은 인돌릴, 푸릴, 페닐 또는 독립적으로 탄소수 1 내지 7의 알킬, -C(CH3)3, -C(CH3)2CH2C(CH3)3, -C(CH3)2CH2CH3, 할로저급알킬, 퍼플루오로알킬, 저급알콕시, 아릴알콕시, 할로 또는 니트로에 의해 임의로 일-또는 이치환된 페닐이며, R4및 R5는 독립적으로 -COCH2R7, -CO2R7, -CONHR7, 게라닐 또는 CH2R3이고, R6는 수소 또는 저급 알킬이며, R7은 게라닐 및이외의 R의 정의 중에서 선택된 잔기이고, A 및 B는 독립적으로 -O-, -S- 또는 -NR6-이며, a는 0 내지 8이고, b는 Y가 S인 경우 1 내지 10이며, Y가 0인 경우 2 내지 10이고, c는 1 내지 3이며, d는 0 내지 9이고, e는 3 내지 18이다.
- 제1항에 있어서, 4-하이드록시-3-[(페틸메톡시)아세틸]-2(5H)-푸란온인 화합물.
- 제1항에 있어서, (Z)-4-하이드록시-3-(1-옥소-9-옥타데세닐)-2(5H)-푸란온인 화합물.
- 제1항에 있어서, (Z,Z)-4-하이드록시-3-(1-옥소-9,12-옥타데카디에틸)-2(5H)-푸란온인 화합물.
- 제1항에 있어서, (Z,Z,Z)-4-하이드록시-3-(1-옥소-9,12,15-옥소데카트리에닐)-2(5H)-푸란온인 화합물.
- 제1항에 있어서, (Z)-4-하이드록시-5,5-디메틸-3-(1-옥소-9-옥타데세닐)-2(5H)-푸란온인 화합물.
- 제1항에 있어서, (Z)-4-하이드록시-3-(1-옥소-6-옥타데세닐)-2-2(5H)-푸란온인 화합물.
- 제1항에 있어서, (Z)-4-하이드록시-3-(1-옥소-8-(2'-옥틸사이클로프로필)옥타닐)-2(5H)-푸란온인 화합물.
- 제1항에 있어서, (Z,Z,Z)-4-하이드록시-3-(1-옥소-6,9,12-옥타데카트리에닐)-2(5H)-푸란온인 화합물.
- 제1항에 있어서, 4-하이드록시-3-[6-(4-클로로펜옥시)-1-옥소헥실]-2(5H)-푸란온인 화합물.
- 제1항에 있어서, 4-하이드록시-3-[1-옥소-8-[2-[(2-펜틸사이클로프로필)메틸]클로로프로필]옥틸-2(5H)-푸란온인 화합물.
- 제1항에 있어서, 4-하이드록시-3-((Z)-1-옥소-10-테트라데세닐)-2(5H)-푸란온인 화합물.
- 제1항에 있어서, (Z)-9-옥타데카노산 5-(2,5-디하이드로-4-하이드록시-3-푸라닐)-5-옥소-1,2-펜탄디일에스테르인 화합물.
- 제1항에 있어서, 4-하이드록시-3-((Z)-1-옥소-9-테트라데세닐)-2-2(5H)-푸란온인 화합물.
- 제1항에 있어서, 4-하이드록시-3-((Z)-1-옥소-9-헥사데세닐)-2(5H)-푸란온인 화합물.
- 제1항에 있어서, 4-하이드록시-3-(1-옥소-9-옥타데시닐)-2(5H)-푸란온인 화합물.
- 제1항에 있어서, 4-하이드록시-3-(1-옥소옥타데실)-2(5H)-푸란온인 화합물.
- 제1항에 있어서, 3-[9-(4-클로로펜옥시)-1-옥소노닐]-4-하이드록시-2(5H)-푸란온인 화합물.
- 제1항에 있어서, 헥시카밤산 5-(2,5-디하이드로-4-하이드록시-2-옥소-3-푸라닐)-5-옥소-1,2-펜탄디일에스테르인 화합물.
- 제1항에 있어서, 도데실카밤산 5-(2,5-디하이드로-4-하이드-2-옥소-3-푸라닐)-5-옥소-1,2-펜탄디일에스테르인 화합물.
- 제1항에 있어서, 4-하이드록시-3-[6-[4-[4-클로로페닐)메톡시펜옥시]]-1-옥소헥실]-2(5H)-푸란온인 화합물.
- 제1항에 있어서, 4-하이드록시-3-[6-[4-(헥실옥시)펜옥시]-1-옥소헥실]-2(5H)-푸란온인 화합물.
- 제1항에 있어서, 4-하이드록시-3-[7-[4-클로로펜옥시)-1-옥소헵틸]-2(5H)-푸란온인 화합물.
- 제1항에 있어서, 3-[(Z)-10-(4-클로로페닐)-1-옥소-9-데세닐]-4-하이드록시-2(5H)-푸란온인 화합물.
- 제1항에 있어서, 4-하이드록시-3-((E)-1-옥소-9-옥타데세닐)-2(5H)-푸란온인 화합물.
- 제1항에 있어서, 3-[6-(4-헵틸펜옥시)-1-옥소헥실]-4-하이드록시-2(5H)-푸란온인 화합물.
- 제1항에 있어서, (Z)-9-옥타데카노산 4-(2,5-디하이드로-4-하이드록시-2-옥소-3-푸라닐)-4-옥소부타노산 에스테르인 화합물.
- 제1항에 있어서, 4-하이드록시-3-[6(1,1,3,3,-테트라메틸부틸)펜옥시)-1-옥소헥실]-2(5H)-푸란온인 화합물.
- 제1항에 있어서, ((Z)-9-옥타데시닐)카밤산 1-[[((E)-3,7-디메틸-2,6-옥타데카디에닐)옥시]메틸]-4-(2,5-디하이드로-4-하이드록시-2-옥소-3-푸라닐)-4-옥소부틸 에스테르인 화합물.
- 제1항에 있어서, 4-하이드록시-3-[10-(4-클로로페닐)-1-옥소데실]-2(5H)-푸란온인 화합물.
- 제1항에 있어서, 4-하이드록시-3-[10-(3,4-디클로로페닐)-1-옥소데실]-2(5H)-푸란온인 화합물.
- 제1항에 있어서, 4-하이드록시-3-[10-[4-(1,1,-디메틸에틸)페닐]1-옥소데실]-2(5H)-푸란온인 화합물.
- 제1항에 있어서, 4-하이드록시-3-[10-(4-브로모페닐)-1-옥소데실]-2(5H)-푸란온인 화합물.
- 제1항에 있어서, 4-하이드록시-3-[10-(4-트리플루오로메틸)-페닐]-2(5H)-푸란온인 화합물.
- 제1항에 있어서, 4-하이드록시-3-[(Z,Z)-1-옥소-9,12-옥타데카디에닐]-2(5H)-티오펜온인 화합물.
- 제1항에 있어서, 4-하이드록시-3-[(Z)-1-옥소-9-테트라데세닐]-2(5H)-티오펜온인 화합물.
- 제1항에 있어서, 4-하이드록시-3-[(Z)-1-옥소-9-테트라데세닐]-2(5H)-티오펜온인 화합물.
- 제1항에 있어서, 4-하이드록시-3-[5-(4-클로로펜옥시)-1-옥소펜틸]-2(5H)-티오펜온인 화합물.
- 제1항에 있어서, 4-하이드록시-3-[(Z,Z,Z)-1-옥소-6,9,12-옥타데카트리에닐]-2(5H)-티오펜온인 화합물.
- 제1항에 있어서, 4-하이드록시-3-[(Z)-1-옥소-6-옥타데세닐-2(5H)-티오펜온인 화합물.
- 제1항에 있어서, 4-하이드록시-3-[(Z)-8-(2-옥틸 사이클로프로필)-1-옥소옥틸]-2(5H)-티오펜온인 화합물.
- 제1항에 있어서, 4-하이드록시-3-[(Z)-1-옥소-2-(2-펜틸사이클로프로필)에틸]-2(5H)-푸란온인 화합물.
- 제1항에 있어서, 4-하이드록시-3-[(Z)-]8-(2-부틸 사이클로 플필)-1-옥소옥틸]-2(5H)-푸란온인 화합물.
- 제1항에 있어서, 4-하이드록시-3-[(Z)-1-옥소-5-(2-운데실사이크롤프로필)펜틸]-2(5H)-푸란온인 화합물.
- 제1항에 있어서, 4-하이드록시-3-[(Z)-1-옥소-2-(2-펜틸사이크로프로필)에틸]-2(5H)-티오펜온인 화합물.
- 병에 걸린 포유동물에 일반식(I)의 화합물의 유효량을 투여함을 특징으로 하여, 포유동물에서 면역염증 상태를 치료하는 방법.상기식에서, Y는 -O- 또는 -S-이고, X는 Y가 0인 경우 -(CH2)aCH3, -(CH2 bZ 또는 -(CH=CH)bZ이며, Y가 S인 경우 -(CH2)aCH3이고, R1및 R2는 각각 독립적으로 수소 또는 저급 알킬이며, Z는 인돌릴, 푸릴, 페닐 또는 독립적으로 탄소수 1 내지 7의 알킬, 할로저급알킬, 퍼플루오로알킬, 저급알콕시, 아르알콕시, 할로 또는 니트로에 의해 임의로 일- 또는 이치환된 페닐이고, a는 Y가 0인 경우 0 내지 20이며, Y가 S인 경우 1 내지 3이고, b는 1 내지 2이다.
- 제46항에 있어서, 화합물이 4-하이드록시-3-(1-옥소데실)-2(5H)-푸란온인 방법.
- 제46항에 있어서, 화합물이 4-하이드록시-3-(1-옥소-3-페닐프로필)-2(5H)-푸란온인 방법.
- 제46항에 있어서, 화합물이 4-하이드록시-3-[3-(1H-인돌-3-일)-]1-옥소프로필]-2(5H)-푸란온인 방법.
- 제46항에 있어서, 화합물이 4-하이드록시-3-[4-(1H-인돌-3-일)-]1-옥소부틸]-2(5H)-푸란온인 방법.
- 제46항에 있어서, 화합물이 (E)-4-하이드록시-3-(3-(4-메톡시페닐)-1-옥소-2-프로페닐)-2(5H)-푸란온인 방법.
- 제46항에 있어서, 화합물이 (E)-4-하이드록시-3-(3-(4-클로로페닐)-1-옥소-2-프로페닐)-2(5H)-푸란온인 방법.
- 제46항에 있어서, 화합물이 (E)-4-하이드록시-3-(3-(페닐)-1-옥소-2-프로페닐)-2(5H)-푸란온인 방법.
- 제46항에 있어서, 화합물이 (E)-4-하이드록시-3-(1-옥소-3-(3-트리플루오로메틸)페닐)-2-프로페닐)-2(5H)-푸란온인 방법.
- 제46항에 있어서, 화합물이 4-하이드록시-3-(1-옥소에이코사노일)-2(5H)-푸란온인 방법.
- 제46항에 있어서, 화합물이 (E)-4-하이드록시-3-(3-(3-니트로페닐)-1-옥소-2-프로페닐)-2(5H)-푸란온인 방법.
- 제46항에 있어서, 화합물이 (E)-3-3-(3-(2,5-디메톡시페닐)-1-옥소-2-프로페닐)-4-하이드록시-2(5H)-푸란온인 방법.
- 제46항에 있어서, 화합물이 (E)-3-3-(3-(2,5-디메톡시페닐)-1-옥소-2-프로페닐)-4-하이드록시-2(5H)-푸란온인 방법.
- 제46항에 있어서, 화합물이 (E)-3-3-(3-(2,5-디메톡시페닐)-1-옥소-2-프로페닐)-4-하이드록시-2(5H)-푸란온인 방법.
- 제46항에 있어서, 화합물이 3-[9-(4-클로로펜옥시)-1-옥소노닐]-4-하이드록시-2(5H)-푸란온인 방법.
- 제46항에 있어서, 화합물이 4-하이드록시-3-[1-옥소헥사데실]-2(5H)-푸란온인 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/685,265 | 1991-04-12 | ||
US07/685,265 US5242945A (en) | 1991-04-12 | 1991-04-12 | Tetronic and thiotetronic acid derivatives as phospholipase a2 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
KR920019770A true KR920019770A (ko) | 1992-11-19 |
Family
ID=24751448
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019920005991A KR920019770A (ko) | 1991-04-12 | 1992-04-10 | 포스포리파제 a₂억제제로서의 테트론산 및 티오테트론산 유도체 |
Country Status (14)
Country | Link |
---|---|
US (1) | US5242945A (ko) |
EP (1) | EP0508690A1 (ko) |
JP (1) | JPH0597839A (ko) |
KR (1) | KR920019770A (ko) |
AU (1) | AU649120B2 (ko) |
CA (1) | CA2065228A1 (ko) |
FI (1) | FI921596A (ko) |
HU (1) | HUT61738A (ko) |
IE (1) | IE920880A1 (ko) |
IL (1) | IL101444A (ko) |
MX (1) | MX9201657A (ko) |
NZ (1) | NZ242301A (ko) |
TW (1) | TW206219B (ko) |
ZA (1) | ZA922181B (ko) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX9302419A (es) * | 1992-04-28 | 1994-03-31 | American Home Prod | Derivados de acido tetronico, tiotetronico y tetramico. |
US5428058A (en) * | 1994-09-28 | 1995-06-27 | American Home Products Corporation | Phospholipase A2 inhibitors |
US5508302A (en) * | 1994-09-28 | 1996-04-16 | American Home Products Corporation | Phospholipase A2 inhibitors |
CA2222471A1 (en) * | 1996-03-27 | 1997-10-02 | Toray Industries, Inc. | Ketone derivatives and medical application thereof |
AU721881B2 (en) * | 1996-03-27 | 2000-07-13 | Toray Industries, Inc. | Ketone derivatives and medicinal use thereof |
GB2321455A (en) * | 1997-01-24 | 1998-07-29 | Norsk Hydro As | Lipophilic derivatives of biologically active compounds |
EP1013178B2 (en) * | 1998-12-22 | 2009-09-16 | Unilever N.V. | Cosmetic use of petroselinic acid |
ES2315365T3 (es) * | 2001-06-13 | 2009-04-01 | Magnachem International Laboratories, Inc. | Formulaciones de lactona y metodo de uso. |
US7323495B2 (en) * | 2002-11-05 | 2008-01-29 | Magnachem International Laboratories, Inc. | Synthetic lactone formulations and method of use |
WO2005102315A1 (en) | 2004-04-23 | 2005-11-03 | Magnachem International Laboratories, Inc. | Synthetic lactone formulations for pain control |
MX2011004331A (es) * | 2008-10-24 | 2011-09-21 | Magnachem Int Lab Inc | Metodo para busqueda de compuestos que interactuan selectivamente con rad9. |
CN117802156A (zh) * | 2024-02-29 | 2024-04-02 | 云南师范大学 | 硼酸转运蛋白基因在转基因植株筛选中的应用及筛选方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1276061A (en) * | 1970-01-14 | 1972-06-01 | Ici Ltd | Tetronic acid derivatives, process for the manufacture thereof, and compositions containing such compounds |
JPS4969659A (ko) * | 1972-10-31 | 1974-07-05 | ||
JPS511633A (ja) * | 1974-06-25 | 1976-01-08 | Toray Industries | Noengeiyosatsukinzai |
US4874782A (en) * | 1985-07-01 | 1989-10-17 | Eli Lilly And Company | Furanone derivatives |
JPS6219582A (ja) * | 1985-07-19 | 1987-01-28 | Agency Of Ind Science & Technol | γ−チオブチロラクトン誘導体の製造方法 |
US5045564A (en) * | 1988-12-07 | 1991-09-03 | Allergan, Inc. | Anti-inflammatory 2-furanones |
-
1991
- 1991-04-12 US US07/685,265 patent/US5242945A/en not_active Expired - Lifetime
-
1992
- 1992-03-19 IE IE088092A patent/IE920880A1/en unknown
- 1992-03-25 ZA ZA922181A patent/ZA922181B/xx unknown
- 1992-04-01 IL IL10144492A patent/IL101444A/xx not_active IP Right Cessation
- 1992-04-03 EP EP19920302947 patent/EP0508690A1/en not_active Ceased
- 1992-04-06 CA CA002065228A patent/CA2065228A1/en not_active Abandoned
- 1992-04-10 NZ NZ242301A patent/NZ242301A/en unknown
- 1992-04-10 KR KR1019920005991A patent/KR920019770A/ko not_active Application Discontinuation
- 1992-04-10 JP JP4090824A patent/JPH0597839A/ja active Pending
- 1992-04-10 TW TW081102798A patent/TW206219B/zh active
- 1992-04-10 AU AU14826/92A patent/AU649120B2/en not_active Ceased
- 1992-04-10 MX MX9201657A patent/MX9201657A/es unknown
- 1992-04-10 HU HU9201238A patent/HUT61738A/hu unknown
- 1992-04-10 FI FI921596A patent/FI921596A/fi unknown
Also Published As
Publication number | Publication date |
---|---|
AU1482692A (en) | 1992-10-15 |
NZ242301A (en) | 1997-03-24 |
ZA922181B (en) | 1993-09-27 |
IL101444A (en) | 1997-02-18 |
EP0508690A1 (en) | 1992-10-14 |
CA2065228A1 (en) | 1992-10-13 |
HU9201238D0 (en) | 1992-07-28 |
IL101444A0 (en) | 1992-12-30 |
FI921596A (fi) | 1992-10-13 |
TW206219B (ko) | 1993-05-21 |
US5242945A (en) | 1993-09-07 |
IE920880A1 (en) | 1992-10-21 |
MX9201657A (es) | 1992-10-01 |
FI921596A0 (fi) | 1992-04-10 |
AU649120B2 (en) | 1994-05-12 |
HUT61738A (en) | 1993-03-01 |
JPH0597839A (ja) | 1993-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR920019770A (ko) | 포스포리파제 a₂억제제로서의 테트론산 및 티오테트론산 유도체 | |
RU2379299C2 (ru) | Производные 5-(бенз-(z)-илиден)тиазолидин-4-она и их применение в качестве иммуносупрессорных агентов | |
AU2008206047B2 (en) | Substituted 1,3-dioxanes useful as PPAR modulators | |
BR0206876A (pt) | Madeira impregnada de polìmero de furano | |
RU95118725A (ru) | Производные оксазолидиндиона, их получение и фармацевтическая композиция | |
RU2004136979A (ru) | (имидазол-1-илметил)пиридазин в качестве блокатора nmda рецептора | |
KR910009688A (ko) | 광색성 화합물,이의 제조방법 및 용도 | |
RU93004992A (ru) | Фенилсульфонамидные соединения и способ лечения | |
AU2007253929A1 (en) | Compounds for the treatment of metabolic disorders | |
KR970701540A (ko) | 카르복실 에스테르를 이용한 태아 헤모글로빈 수준의 증가 방법(increasing fetal hemoglobin levels using carboxylic esters) | |
KR880000370A (ko) | 치환된 페닐화합물 | |
RU2005117964A (ru) | Замещенные 4-алкоксиоксазолпроизводные в качестве агонистов ppar | |
BR0312956A (pt) | Madeira impregnada com polìmero de furano | |
KR910015552A (ko) | 항당뇨병성 활성을 가진 티아졸리딘 유도체, 그의 제조 방법 및 용도 | |
WO2016057658A9 (en) | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof | |
KR890000477A (ko) | 신규 화합물들 | |
EP0128010B1 (en) | 1,4-dihydropyridine derivative, process for production thereof and pharmaceutical use thereof | |
RU2005109163A (ru) | НОВЫЕ СОЕДИНЕНИЯ 2-АРИЛТИАЗОЛА В КАЧЕСТВЕ АГОНИСТОВ PPARα И PPARγ | |
RU2008129377A (ru) | Замещенные производные имидазолина | |
RU2005119172A (ru) | Производные 4-анилинхиназолина для лечения патологического роста клеток | |
RU98100257A (ru) | Производные оксазолидинона, их получение и их применение в терапии | |
SU725406A1 (ru) | Эфиры диметил дигидропиридин диКАРбОНОВОй КиСлОТы,ОблАдАющиЕ АНТи-МЕТАСТАТичЕСКОй АКТиВНОСТью | |
KR20000065039A (ko) | 폐순환 개선제 | |
KR910004566A (ko) | 이미노 치환 피리딘류 | |
RU2022122609A (ru) | Способ лечения вирусного заболевания (варианты) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |